Lyell Immunopharma's (LYEL) "Buy" Rating Reaffirmed at Needham & Company LLC

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $44.00 price objective on the stock. Needham & Company LLC's price objective indicates a potential upside of 111.03% from the company's current price.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen cut Lyell Immunopharma from a "hold" rating to a "sell" rating in a report on Saturday, May 2nd. Zacks Research cut Lyell Immunopharma from a "hold" rating to a "strong sell" rating in a report on Tuesday, April 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Citizens Jmp initiated coverage on Lyell Immunopharma in a research report on Monday, March 9th. They set a "market outperform" rating and a $34.00 price objective for the company. Finally, Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the company an "outperform" rating in a research note on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.00.

Lyell Immunopharma Stock Up 1.1%

Lyell Immunopharma stock opened at $20.85 on Thursday. The firm has a market capitalization of $486.43 million, a PE ratio of -1.28 and a beta of -0.05. Lyell Immunopharma has a 52 week low of $7.65 and a 52 week high of $45.00. The firm's 50-day simple moving average is $22.25 and its 200 day simple moving average is $23.50.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.37) by $1.27. Lyell Immunopharma had a negative net margin of 762,355.56% and a negative return on equity of 90.52%. The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.01 million. On average, research analysts expect that Lyell Immunopharma will post -10.45 EPS for the current fiscal year.

Insider Buying and Selling at Lyell Immunopharma

In other Lyell Immunopharma news, COO Stephen J. Hill sold 1,236 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $28,910.04. Following the transaction, the chief operating officer owned 17,795 shares of the company's stock, valued at $416,225.05. This represents a 6.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Gary K. Lee sold 1,671 shares of the firm's stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $39,084.69. Following the sale, the insider owned 16,938 shares in the company, valued at $396,179.82. This trade represents a 8.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 11,310 shares of company stock worth $264,285. Insiders own 6.20% of the company's stock.

Institutional Trading of Lyell Immunopharma

Hedge funds have recently added to or reduced their stakes in the business. Foresite Capital Management V LLC lifted its holdings in shares of Lyell Immunopharma by 17.3% during the 3rd quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company's stock worth $7,748,000 after acquiring an additional 70,426 shares during the period. Takeda Pharmaceutical Co. Ltd. increased its holdings in shares of Lyell Immunopharma by 33.3% during the 3rd quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company's stock worth $891,000 after buying an additional 13,722 shares during the last quarter. Barclays PLC increased its holdings in shares of Lyell Immunopharma by 1,239.5% during the 4th quarter. Barclays PLC now owns 15,967 shares of the company's stock worth $491,000 after buying an additional 14,775 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Lyell Immunopharma in the 4th quarter worth $382,000. Finally, Two Sigma Investments LP boosted its holdings in Lyell Immunopharma by 107.0% in the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company's stock valued at $338,000 after acquiring an additional 10,768 shares during the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.